Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,248 questions in 108 reviews · Stroke
current versionsNo studies 275 · 22%Ungraded 56 · 4.5%Very low 269 · 21.6%Low 349 · 28%Moderate 216 · 17.3%High 83 · 6.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Balance post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Self‐reported health‐related quality of life post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | 3 studies · 569 participants | Moderate |
Intervention NR Depression post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | 6 studies · 1145 participants | Moderate |
Intervention NR Upper limb function post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | 2 studies · 54 participants | Low |
Intervention NR Self‐care and domestic life Post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mobility post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Balance post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | 3 studies · 106 participants | Low |
Intervention NR Self‐reported health‐related quality of life post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Depression post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Upper limb function post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | 3 studies · 170 participants | Low |
Intervention NR Independence in ADL post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | 2 studies · 661 participants | Moderate |
Intervention NR Self‐care and domestic life post‐intervention · people with stroke Telerehabilitation services for stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Sexual function (primary outcome) · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | 1 study · 114 participants | Very low |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Quality of life (secondary outcome) · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | 1 study · 68 participants | Low |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Psychological well‐being (secondary outcome) · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | 1 study · 68 participants | Low |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Satisfaction with intervention (secondary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Marital/relationship/partner satisfaction (secondary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Adverse effects (secondary outcome) Outcome measure: adverse effects · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Psychological well‐being (secondary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Sexual satisfaction (primary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Quality of life (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Psychological well‐being (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Satisfaction with intervention (secondary outcome) Not addressed · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
Pharmacological interventions vs placebo/usual care or different forms of intervention Marital/relationship/partner satisfaction (secondary outcome) · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | 1 study · 114 participants | Very low |
Pharmacological interventions vs placebo/usual care or different forms of intervention Adverse effects (secondary outcome) Outcome measure: adverse effects*** · men (aged between 23 and 45) with premature ejaculation within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | 1 study · 114 participants | Very low |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Sexual function (primary outcome) · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | 1 study · 68 participants | Low |
Non‐pharmacological interventions vs placebo/usual care or different forms of intervention Sexual satisfaction (primary outcome) Not addressed · people within 3 months after stroke Interventions for sexual dysfunction following stroke (2020) · Cochrane | no estimate extracted | NR | No studies |
NOAC (rivaroxaban) vs standard‐dose VKA Any thromboembolic event · people with antiphospholipid syndrome and a history of stroke and or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 4.08 [0.48, 34.79] | 3 studies · 425 participants | Moderate |
High‐dose VKA vs standard‐dose VKA All‐cause mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 1.53 [0.27, 8.79] | 2 studies · 223 participants | Low |
High‐dose VKA vs standard‐dose VKA Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 1.37 [0.26, 7.12] | 2 studies · 223 participants | Low |
High‐dose VKA vs standard‐dose VKA Any bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 1.56 [0.93, 2.62] | 2 studies · 223 participants | Low |
High‐dose VKA vs standard‐dose VKA Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | no estimate extracted | NR | No studies |
Standard‐dose VKA plus single antiplatelet agent vs standard‐dose VKA Any thromboembolic event · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 2.14 [1.04, 4.43] | 1 study · 82 participants | Low |
Standard‐dose VKA plus single antiplatelet agent vs standard‐dose VKA Major bleeding · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 7.42 [0.91, 60.7] | 1 study · 82 participants | Low |
Standard‐dose VKA plus single antiplatelet agent vs standard‐dose VKA All‐cause mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 0.49 [0.02, 11.68] | 1 study · 82 participants | Very low |
Standard‐dose VKA plus single antiplatelet agent vs standard‐dose VKA Strokea · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 4.45 [0.48, 41] | 1 study · 82 participants | Low |
Standard‐dose VKA plus single antiplatelet agent vs standard‐dose VKA Minor bleedingb · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 1.29 [0.86, 1.94] | 1 study · 82 participants | Low |
Standard‐dose VKA plus single antiplatelet agent vs standard‐dose VKA Adverse events · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | no estimate extracted | NR | No studies |
NOAC (rivaroxaban) vs standard‐dose VKA Major bleeding · people with antiphospholipid syndrome and a history of stroke and or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 1.1 [0.45, 2.68] | 3 studies · 425 participants | Moderate |
Standard‐dose VKA plus single antiplatelet agent vs single antiplatelet agent Major bleeding (minor cerebral hemorrhage) · people with antiphospholipid syndrome, with previous stroke Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 0.4 [0.02, 8.78] | 1 study · 20 participants | Very low |
Standard‐dose VKA plus single antiplatelet agent vs single antiplatelet agent Stroke · people with antiphospholipid syndrome, with previous stroke Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 0.14 [0.01, 2.6] | 1 study · 40 participants | Very low |
Standard‐dose VKA plus single antiplatelet agent vs single antiplatelet agent Any bleeding that does not meet criteria for major bleeding ‐ Gastrointestinal bleeding (no definition) · people with antiphospholipid syndrome, with previous stroke Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 3.6 [0.16, 79.01] | 1 study · 20 participants | Very low |
Standard‐dose VKA plus single antiplatelet agent vs dual antiplatelet agent Stroke · people with antiphospholipid syndrome, with previous stroke Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 5 [0.26, 98] | 1 study · 40 participants | Very low |
Dual antiplatelet agent vs single antiplatelet agent Stroke · people with antiphospholipid syndrome, with previous stroke Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 0.14 [0.01, 2.6] | 1 study · 40 participants | Very low |
NOAC (rivaroxaban) vs standard‐dose VKA All‐cause mortalitya · people with antiphospholipid syndrome and a history of stroke and or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 1.45 [0.44, 4.78] | 3 studies · 425 participants | Moderate |
NOAC (rivaroxaban) vs standard‐dose VKA Strokea · people with antiphospholipid syndrome and a history of stroke and or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 14.13 [1.87, 106.81] | 3 studies · 425 participants | Moderate |
NOAC (rivaroxaban) vs standard‐dose VKA Mean quality of life ‐ health utility · people with antiphospholipid syndrome and a history of stroke and or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | no estimate extracted | 1 study · 111 participants | Low |
NOAC (rivaroxaban) vs standard‐dose VKA Mean quality of life ‐ health state · people with antiphospholipid syndrome and a history of stroke and or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | no estimate extracted | 1 study · 112 participants | Low |
NOAC (rivaroxaban) vs standard‐dose VKA Clinically relevant non‐major bleeding · people with antiphospholipid syndrome and a history of stroke and or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 1.7 [0.69, 4.19] | 2 studies · 302 participants | Moderate |
High‐dose VKA vs standard‐dose VKA Any thromboembolic event · people with antiphospholipid syndrome and a history of stroke or thromboembolic events Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in… (2020) · Cochrane | RR 2.22 [0.79, 6.23] | 2 studies · 223 participants | Low |